Clinical Trial Update: Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is investigating allogeneic hematopoietic stem cell transplantation for patients with GATA2 mutations, currently in recruitment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gata2 Deficiency
• Immunodeficiency
• Myelodysplastic Syndrome

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: GATA2, Immunodeficiency | Phase 2 | Status: RECRUITING